LCM
LGND icon

Landscape Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Landscape Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8,741
Closed -$543K – 739
2019
Q3 		$543K Buy
+8,741
New +$549K 0.04% 383
2015
Q1 		– Sell
-10,420
Closed -$346K – 606
2014
Q4 		$346K Buy
+10,420
New +$339K 0.17% 159

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Landscape Capital Management's LGND Position: Q4 2019 in Review

Landscape Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 8,741 shares — an estimated $543K sold.

Landscape Capital Management first reported a position in LGND in Q4 2014 and held it in 2 quarters. The position peaked at $543K in Q3 2019. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

  • Landscape Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Landscape Capital Management sold 8,741 Ligand Pharmaceuticals shares in Q4 2019, an estimated $543K.
  • Landscape Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Landscape Capital Management's Ligand Pharmaceuticals position peaked at $543K in Q3 2019.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Landscape Capital Management's 13F filing for Q4 2019, filed 11 Feb 2020.